Andrew McConaghie is pharmaphorum’s managing editor. He writes on a range of topics covering pharmaceutical and biotech R&D, marketing and market access, and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Pharma company Shire and tech giant Microsoft are to team up with Eurodis, a not-for-profit group representing 700 rare disease organisations, with the goal of cutting the long wait most patients with rare conditions endure before diagnosis.
A new report from the Nuffield Trust backs concerns among general practice that new tech-based entrants could do more harm than good for the NHS. But that doesn’t mean the search for new solutions ends there